key: cord-0907318-5usj8x3e
authors: Anugulruengkitt, Suvaporn; Teeraananchai, Sirinya; Chantasrisawad, Napaporn; Promsena, Pathariya; Jantarabenjakul, Watsamon; Puthanakit, Thanyawee
title: Clinical Outcomes of Pediatric COVID-19 in a Tertiary Care Center in Bangkok, Thailand
date: 2021-11-18
journal: IJID Regions
DOI: 10.1016/j.ijregi.2021.11.003
sha: 63f00ca107d3a1d027bc7ef5193c996800935da9
doc_id: 907318
cord_uid: 5usj8x3e

Objective To describe the clinical characteristics and outcomes of pediatric COVID-19 in Thailand where favipiravir is the mainstay antiviral treatment. Methods An observational cohort study, hospital-based COVID-19 among children was conducted. The study included children age younger than 15 years with confirmed positive RT-PCR for SARS-CoV-2 from nasopharyngeal swab. Results From April to July 2021, 416 cases with median (IQR) age of 7.1 (2.7-11.6) years were included. The spectrum of diseases included 82 (20%) asymptomatic, 232 (56%) mild, and 102 (24%) pneumonia. Abnormal chest x-ray findings included ground glass opacities (46%), focal infiltrations (27%), perihilar opacities (19%), reticular infiltrations (15%), and other non-specific findings (4%). Only 12 children (3%) required oxygen support. Favipiravir was prescribed to 129 children (31%); 102 patients with pneumonia and 27 patients at risk for disease progression. Pneumonia was more common in age less than 3 years when compared to those aged 3-<12 years (aOR 0.30, 95%CI 0.17-0.52), and 12-15 years (aOR 0.40, 95%CI 0.21-0.77), and in patients with comorbidities (aOR 2.36, 95%CI 1.09-5.12). Conclusions One-fourth of pediatric COVID had pneumonia, but only few required oxygen support. Favipiravir has been reported as an off-label uses in pediatric COVID-19 in recent outbreak in Bangkok.

Conclusions: One-fourth of pediatric COVID had pneumonia, but only few required oxygen support. Favipiravir has been reported as an off-label uses in pediatric COVID-19 in recent outbreak in Bangkok.

Since December 2019, Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged and spread globally. Although children usually have milder disease than adults, the proportion of infected children were increasing (Ludvigsson et al., 2020) . In United States (US), children were accounted for 10% of cases in 2020 and increased to 15% of cases in 2021 (Pediatrics AAP, 2021). Data on clinical outcomes of pediatric COVID-19 cases in Asia are limited. In Thailand, the third outbreak has been resurged in April 2021, coincided with an increasing proportion of the Delta variant which is more transmissible and might cause more severe illness. The percentage of Delta variant in Bangkok increased from 22.5% in April to 86.2% in July (Ministry of Public Health, Thailand, 2021).

According to Thai National Guideline, favipiravir, a nucleotide analog targeting the viral RNA-dependent RNA polymerase (Delang et al., 2018) , is the treatment options using in patients at risk to develop severe disease and for mild severity of pneumonia. Remdesivir is recommended for severe disease due to limited access. Anti-SARS-CoV-2 monoclonal antibodies was not available during the study period. The objectives of this study were to describe clinical characteristics of pediatric COVID-19 cases and to assess factors associated with pneumonia and report experiences of favipiravir uses in children.

The study was an observational cohort of confirmed COVID-19 in patients aged <15 years in a tertiary care center, King Chulalongkorn Memorial Hospital (KCMH), Bangkok, Thailand during April to July 2021. KCMH is a 1,500-bed tertiary care hospital collaborated with the Thai Red Cross Emerging Infectious Diseases (EID) Clinical Center, the country's largest EID clinic. In the time of study conduct, all confirmed COVID-19 cases had to be hospitalized for isolation and COVID-19 vaccines were not available for children. Inclusion criteria were hospitalized patients aged <15 years who had positive reverse transcriptasepolymerase chain reaction (RT-PCR) for SARS-CoV-2. All hospitalized confirmed cases underwent chest x-ray regardless of symptoms. Basic laboratory tests such as complete blood counts were not performed in all cases but only if clinically indicated. The severity was classified into 1) asymptomatic infections, 2) mild: upper respiratory tract infection or mild other symptoms, 3) moderate: pneumonia either with clinically or abnormal radiological findings, 4) severe: pneumonia with desaturation or need for respiratory support, 5) critical: respiratory failure or life-threatening conditions (Dong et al., 2020) . To consider associated factors with pneumonia, we grouped asymptomatic/mild to non-pneumonia subgroup, and moderate/severe/critical to pneumonia subgroup. Thai guideline recommended favipiravir 35 mg/kg/dose twice daily on day 1, then 15 mg/kg/dose twice daily on day 2-5. Corticosteroid, dexamethasone 0.15 mg/kg/dose once daily, were prescribed for up to 5-10 days in patients with COVID-19 who require supplemental oxygen or in patients with persisted fever during inflammatory phase.

Study data were collected and managed using Research Electronic Data Capture.

Baseline characteristics were reported as mean (SD) or median (interquartile range, IQR) for continuous variables. Categorical data were constructed using frequencies and percentages. Chisquare test or Fisher's exact test were used to compare categorical variables as appropriate and

Mann-Whitney U test to compare continuous variables. Factors associated with pneumonia cases were analyzed using logistic regression. Multivariable models were developed by adjusting for covariates with p<0.10 in univariable models. All p-values reported were two-sided. Statistical significance was defined as p<0.05. Statistical analysis was performed using Stata version 15.1 (Stata Corp., College Station, Texas).

From April to July 2021, there were 416 pediatric confirmed COVID-19 cases. The median (IQR) age was 7.1 (2.7-11.6) years, and 42 (10%) cases were younger than 1 year.

Thirty-seven (9%) had underlying conditions. Most of them (377, 91%) contacted confirmed COVID-19 cases from household members. Characteristics of confirmed COVID-19 cases were shown in Table 1 . There were 82 (20%) asymptomatic infections, 232 (56%) mild, 90 (21%) moderate, 12 (3%) severe and no critical case.

Grouping asymptomatic and mild resulted in 314 non-pneumonia subgroup and moderate/severe/critical resulted in 102 cases in pneumonia subgroup. Median age among pneumonia subgroup was significantly younger than non-pneumonia subgroup; 4.9 vs 7.4 years, (p=0.014). The proportion of patients with underlying conditions was significantly higher in pneumonia subgroup; 15% vs 7% (p=0.018) ( Table 1) . Patient who aged 3-<12 years and 12-15 years had a reduction of having pneumonia by 70% and 60% respectively when compared to those age <3 years. Patients with comorbidities had higher risk of pneumonia (aOR=2.36, 95%CI 1.09-5.12). We also found that rates of pneumonia significantly increased from April to Jul 2021 (p=0.008) (Supplementary material). Other factors associated with an increased risk of pneumonia were obesity. (Table 2) Chest x-rays were performed among 410 patients. Ninety-four patients (23%) had abnormal findings included 46% ground glass opacities, 27% focal infiltrations, 19% perihilar opacities, 15% reticular infiltrations, and 4% other non-specific findings. Regarding specific treatment, 129 (31%) received favipiravir consisted of 102 pneumonia cases and 27 patients who had risk factors for severe disease e.g. comorbidities, under 1 year of age. Among 129 patients received favipiravir, 120 (93%) had no fever after 72 hours of treatment. None had drug discontinuation due to clinical adverse side effects. Only 3 (0.7%) received remdesivir (2 gastrointestinal tract absorption problem, and 1 immunocompromised patient who had persisted fever after receiving favipiravir for 48 hours). Steroid were prescribed in 13 patients (3.2%).

None received anticoagulant. Twelve children (2.9%) required oxygen support. None required invasive ventilation.

Our study described the clinical data and outcomes of confirmed pediatric COVID-19 in the context of tertiary care center in recent outbreak in Bangkok. We observed an increased proportion of symptomatic infection and pneumonia cases from April to July 2021. The reason may explain from the Delta variant which became the dominant strain in the setting. Similar to a study in the US showing an increase in COVID-19-associated hospitalization rates which might be from increased community SARS-CoV-2 transmission or increased disease severity caused by the Delta variant (Delahoy et al., 2021) . Children usually having mild symptoms but severe cases should be cautioned in younger age, obese, or whom with comorbidities. These findings were also described in the pediatric COVID-19 cohort in the US and medical personnel should apply this knowledge to early recognition and improve treatment outcomes (Martin et al., 2021) .

In Turkey where drug availability is also limited, favipiravir is recommended for severe pediatric COVID-19 cases. Ozsurekci reported favipiravir use in pediatric patients with renal impairment and showed well tolerated without major side effects (Ozsurekci et al., 2021) .

Favipiravir is not approved for COVID-19 due to the lack of proved efficacy. However, there is an ongoing phase 3 study (PRESECO) of favipiravir for adults with mild to moderate symptoms COVID-19 infections in the US which expect to report results by 2021 (Appili Therapeutics, 2021). Here we reported experience of using favipiravir as therapeutic options in children due to limited drug availability of approved antiviral agents.

Page 8 of 13

The strength of this study is its reports on clinical data and outcomes of pediatric COVID-19 confirmed by RT-PCR. To the best of our knowledge, there are few reports on clinical data and outcomes in pediatric COVID-19 cases in developing countries and in Asia.

Our study also had some limitations. First, data on SARS-CoV-2 strain and viral clearance after treatment were not confirmed in the study. The cause of more severe disease in the later month of diagnosis with assumption on Delta variants may be uncertain. Overload of cases in health system also leads to delay in treatment and may affect severity. Additionally, data on further follow-up for post covid syndrome and multisystem inflammatory syndrome in children (MIS-C) are needed in the future. In conclusion, based on hospitalized pediatric COVID-19, one-fourth developed pneumonia, but only few required oxygen support. Favipiravir has been reported as an off-label uses in pediatric COVID-19 in recent outbreak in Bangkok.

The authors declare no conflict of interest

This study was approved by the Faculty of Medicine, Chulalongkorn University. 

Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil

Among Children and Adolescents -COVID-NET, 14 States

Department of Medical Sciences, Ministry of Public Health, Thailand. Surveillance of SARS-CoV-2 strains in Thailand

Epidemiology of COVID-19 Among Children in China

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults

Children with SARS-CoV-2 in the National COVID Cohort Collaborative (N3C)

Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?

State-level data report

The authors would like to thank all healthcare workers who responsible in patients care at EID services, KCMH. We also would like to thank Mr.Ratchanon Thongnil, Dr.Rapisa Nantanee, and Dr.Puneyawee Aikphaibul for data collection.

Page 9 of 13